Sandoz Group AG
SIX:SDZ
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
25.01
40.62
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Sandoz Group AG
Cash Equivalents
Sandoz Group AG
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Cash Equivalents
$1.1B
|
CAGR 3-Years
205%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Novartis AG
SIX:NOVN
|
Cash Equivalents
$9.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Roche Holding AG
SIX:ROG
|
Cash Equivalents
CHf5.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Sandoz Group AG
Glance View
Sandoz Group AG, a global leader in generics and biosimilars, operates as a subsidiary of the Swiss pharmaceutical giant Novartis. Established in 1886, Sandoz has a storied history rooted in innovation and a commitment to providing high-quality and affordable medications. The company's mission focuses on improving patient access to essential treatments, making it a critical player in the healthcare landscape. With a diverse portfolio of over 1,000 generic pharmaceuticals and a growing range of biosimilars, Sandoz strategically positions itself to meet the increasing global demand for cost-effective alternatives to brand-name drugs. Its robust research and development efforts ensure that Sandoz remains at the forefront of medicinal advancements, enhancing its competitive edge in an ever-evolving market. For investors, Sandoz Group AG represents an attractive opportunity, driven by several key factors. The global generics market, valued at hundreds of billions, is projected to grow as healthcare costs rise and countries push for more budget-friendly solutions. Furthermore, Sandoz's exceptional reputation for quality and compliance has made it a trusted name among healthcare providers and patients alike. The company's efforts in biotechnology and its expanding portfolio of biosimilars position it well to capture new market segments, especially as patents for major biologics expire. With a strong foundation, a commitment to innovation, and strategic growth initiatives, Sandoz offers not just stability but also potential for significant long-term returns in the dynamic pharmaceutical industry.
See Also
What is Sandoz Group AG's Cash Equivalents?
Cash Equivalents
1.1B
USD
Based on the financial report for Dec 31, 2023, Sandoz Group AG's Cash Equivalents amounts to 1.1B USD.
What is Sandoz Group AG's Cash Equivalents growth rate?
Cash Equivalents CAGR 3Y
205%
Over the last year, the Cash Equivalents growth was 1 399%. The average annual Cash Equivalents growth rates for Sandoz Group AG have been 205% over the past three years .
You don't have any saved screeners yet
